Substance P induced preprotachykinin-a mRNA, neutral endopeptidase mRNA and substance P in cultured normal fibroblasts.
In certain skin diseases, stress can modulate the induction and/or progression of cutaneous manifestations. However, little is known about the circuit in neuroendocrine and in the immune systems of the skin. To address this question, we have analyzed the regulatory mechanisms of autocrine induction of substance P (SP) by cultured normal human fibroblasts that compose the major population of the skin and might augment stress-induced skin inflammatory responses. In nonstimulated conditions, normal fibroblasts express a moderate amount of preprotachykinin-A (PPT-A), a precursor of SP mRNA, and exogenous SP significantly upregulated PPT-A mRNA expression. Maximum response of SP peptide and SP mRNA in fibroblasts was observed 1-3 h after stimulation with SP. In contrast, the expression of neutral endopeptidase (NEP), a cell surface peptide with hydrolyzing activity of SP, was increased in fibroblasts stimulated with SP after 24 h. The administration of NEP inhibitor (phosphoramidon) to the fibroblasts induced higher SP production. In addition, the neurokinin (NK) receptor antagonists (spantide, FK224 and FK888) and protein synthesis inhibitor (cycloheximide) inhibited SP production by 30-40% of control response. In immunostaining study, specific cytoplasmic staining of SP was observed in fibroblasts stimulated with SP. Finally, we confirmed that the nucleotide sequence of the PPT-A expressed in fibroblasts perfectly corresponded to the gene bank human PPT-A cDNA. This is the first report that SP mRNA, NEP mRNA and SP peptide can be induced by normal human skin fibroblasts in response to exogenous SP, and that fibroblast-derived SP might play an important role in the induction and acceleration of certain cutaneous diseases.
Bae
Sang-Jae
SJ
Department of Dermatology, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. s-jbae@net.nagasaki-u.ac.jp
Matsunaga
Yoshitaka
Y
Takenaka
Motoi
M
Tanaka
Yoichi
Y
Hamazaki
Yoichiro
Y
Shimizu
Kazuhiro
K
Katayama
Ichiro
I
D002478:Cells, Cultured; D003513:Cycloheximide / Q000494:pharmacology; D004151:Dipeptides / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006020:Glycopeptides / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000494:pharmacology; D015260:Neprilysin / Q000096:biosynthesis* / Q000235:genetics; D064729:Neurokinin-1 Receptor Antagonists; D010456:Peptides, Cyclic / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D011498:Protein Precursors / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D012867:Skin / Q000276:immunology* / Q000378:metabolism; D013373:Substance P / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D015320:Tachykinins / Q000096:biosynthesis* / Q000235:genetics
D004151:Dipeptides; D006020:Glycopeptides; D007211:Indoles; D064729:Neurokinin-1 Receptor Antagonists; D010456:Peptides, Cyclic; D011480:Protease Inhibitors; D011498:Protein Precursors; D012333:RNA, Messenger; D015320:Tachykinins; C044206:preprotachykinin; C075570:FK 224; C078949:FK 888; D013373:Substance P; C042867:spantide; D003513:Cycloheximide; D015260:Neprilysin; C008890:phosphoramidon